The Motley Fool··Jonathan PoncianoSiren Doubles Down on Cancer Play: $29M Erasca Bet Despite 700% Rally
Siren hedge fund adds $29M to $ERAS position amid 700% surge, signaling conviction in RAS-targeted cancer therapy potential.
ERASstock surgeoncology